Immunotherapy Bridge puts resistance, cold tumors, and combination strategies at the center of cancer care
The central problem in modern cancer immunotherapy is no longer whether the immune system can be mobilized. It is why so many tumors still escape that pressure, either by never attracting an effective immune response in the first place or by learning how to evade it after treatment begins.
That tension framed the discussions at Immunotherapy Bridge in Naples on November 30 and December 1, 2022, where investigators focused on the next phase of treatment development: approaches designed for patients who do not respond adequately to current regimens, for tumors with low intrinsic immunogenicity, and for the acquired resistance that limits durable benefit even after an initial response. The meeting report published in the Journal of Translational Medicine situates these efforts within a broader immuno-oncology reality. Outcomes have improved across cancer types, but the gains are uneven, and the remaining failures are clinically consequential.
The report places immunotherapy at an inflection point. Existing immune checkpoint blockade and other immune-based treatments have changed the standard of care in multiple malignancies, yet response rates remain incomplete and are often poor in so-called immunologically cold tumors. Those cancers do not naturally present the inflammatory environment needed to recruit and sustain antitumor immunity, so a single checkpoint inhibitor is often not enough to convert biology into benefit. The meeting therefore concentrated on strategies intended to deepen immune engagement rather than simply repeat the same mechanism with incremental variation.
Adoptive cell transfer and engineered cellular approaches move to the foreground
A major theme was adoptive cell transfer (ACT), a strategy built on the idea that antitumor immune cells can be collected, expanded, redirected, or otherwise enhanced outside the body and then returned with greater functional capacity. In principle, ACT bypasses some of the barriers that make native antitumor immunity so unreliable inside a patient with advanced cancer. Instead of waiting for the host immune response to generate the right cells in the right quantity, ACT provides a more deliberate cellular intervention.
This matters most in tumors that have already proven resistant to conventional immune stimulation. If a cancer suppresses T-cell priming, excludes immune cells from the tumor microenvironment, or erodes effector function after infiltration, then a therapy designed to deliver more capable cells directly into the system offers a rational alternative. The meeting report emphasizes cell therapies as a core direction for the field, reflecting how much attention is shifting toward treatments that are not limited to checkpoint inhibition alone.
One sentence captures the problem cleanly: many tumors are not lacking immune targets; they are lacking effective immune access.
Therapeutic vaccines and immune priming remain part of the same problem
The report also centers therapeutic vaccines, another strategy intended to alter the immune system’s relationship with cancer rather than merely block inhibitory signals. Vaccines in this setting are not preventive tools; they are intended to direct or amplify antitumor responses in patients who already have disease. Their appeal lies in the possibility of creating a more specific and sustained immune attack, particularly when paired with other agents that can prevent exhaustion or blunt suppressive pathways.
Mechanistically, vaccines are attractive because they may help solve an upstream failure in immune recognition. A tumor that stays invisible to the immune system will not respond robustly to treatments that depend on preexisting immunity. By pushing the immune response toward recognition of tumor-associated antigens, vaccines may help initiate the cascade that checkpoint inhibitors then preserve. The report places these agents among the emerging therapies being explored for inadequate responders, a group that remains one of the most important unmet needs in oncology.
New checkpoint inhibitors are being developed for combinations, not isolation
The meeting also reviewed novel immune checkpoint inhibitors, but the framing was noticeably different from the early checkpoint era. The emphasis is now on combinations and on extending benefit into cancers where current options are weak. That shift reflects a practical lesson from the last several years of immuno-oncology: a single checkpoint axis rarely explains all immune escape. Tumors often use multiple overlapping inhibitory signals, and they can adapt quickly when one pathway is blocked.
For that reason, the report describes emerging evidence of improved responses with new immunotherapy agents often used alongside existing agents. Combination therapy is not simply a way to intensify treatment. It is a response to tumor complexity. Some tumors need immune priming, others need relief from suppression, and many require both. In this context, combination development is less about stacking drugs and more about matching mechanisms to the biological barriers preventing response.
Cold tumors and acquired resistance define the next research agenda
Two categories shaped the entire discussion: tumors that are immunologically cold and tumors that have developed acquired resistance. The first category is difficult because the immune system never meaningfully enters the tumor ecology. The second is difficult because the tumor has already demonstrated an ability to adapt under therapeutic pressure. Both groups expose the limits of approaches that work well only when a preexisting immune response is already in place.
The report makes clear that the next generation of immunotherapy has to operate in both settings. In cold tumors, the challenge is to ignite immunity. In resistant tumors, the challenge is to preserve or restore it after it has been blunted. Those are different biological problems, and they are unlikely to be solved by the same intervention alone. This is why the field is moving toward integrated strategies that combine cellular therapy, vaccine-based priming, and checkpoint modulation.
The clinical consequence is straightforward: patients whose cancers fall outside the current responder profile still need viable immune-based options.
A field expanding beyond a single mechanism
Immunotherapy Bridge was organized by the Fondazione Melanoma Onlus in Naples in collaboration with the Society for Immunotherapy of Cancer, and the meeting brought together investigators working across the immuno-oncology spectrum. The breadth of contributors reflects the scope of the challenge. The field is no longer limited to identifying whether immune checkpoint blockade works. It is now asking how to make immune-based treatment effective in settings where standard approaches fall short, and how to engineer responses that are durable enough to matter clinically.
The report does not present a single practice-changing trial result. Instead, it captures the direction of the field: more focus on cell therapies, more interest in therapeutic vaccines, and more effort to design checkpoint inhibition and other immune strategies for patients who have been excluded by tumor biology. The unanswered issue is not whether immunotherapy can work. The issue is which combinations, in which tumors, and through which immune mechanisms will finally extend benefit to the patients who still do not respond.